Holen Sie sich die Stockscreener-App
1.54
0.65%
-0.01
Handel nachbörslich:
1.53
-0.01
-0.65%
Schlusskurs vom Vortag:
$1.55
Offen:
$1.56
24-Stunden-Volumen:
7,863
Relative Volume:
0.57
Marktkapitalisierung:
$17.99M
Einnahmen:
$996.00K
Nettoeinkommen (Verlust:
$-6.09M
KGV:
0.343
EPS:
4.49
Netto-Cashflow:
$-9.76M
1W Leistung:
-1.91%
1M Leistung:
-6.24%
6M Leistung:
-18.09%
1J Leistung:
-30.32%
1-Tages-Spanne:
$1.5201
$1.57
1-Wochen-Bereich:
$1.52
$1.5854
52-Wochen-Spanne:
$1.4302
$3.07
Therapeuticsmd Inc Stock (TXMD) Company Profile
Firmenname
Therapeuticsmd Inc
Sektor
Telefon
561-961-1900
Adresse
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-08-07 | Herabstufung | Jefferies | Hold → Underperform |
| 2020-05-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-12-02 | Eingeleitet | Guggenheim | Buy |
| 2019-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-30 | Fortgesetzt | Noble Capital Markets | Outperform |
| 2018-06-15 | Eingeleitet | JP Morgan | Overweight |
| 2017-09-08 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2017-07-11 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2017-05-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2016-11-22 | Fortgesetzt | Jefferies | Buy |
| 2016-11-22 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-07 | Fortgesetzt | Guggenheim | Buy |
| 2016-04-04 | Eingeleitet | Goldman | Buy |
| 2015-12-08 | Bestätigt | Jefferies | Buy |
| 2015-12-08 | Bestätigt | Stifel | Buy |
| 2015-09-21 | Bestätigt | Jefferies | Buy |
| 2015-06-09 | Eingeleitet | Guggenheim | Buy |
| 2014-07-08 | Eingeleitet | FBR Capital | Outperform |
| 2014-04-17 | Bestätigt | Noble Financial | Buy |
| 2014-01-28 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Therapeuticsmd Inc Aktie (TXMD) Neueste Nachrichten
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD Inc. stock remains steady Thursday, still outperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock rises Tuesday, still underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock rises Thursday, still underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD Inc. stock remains steady Thursday, underperforms market - MarketWatch
TherapeuticsMD Inc. stock remains steady Friday, underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Sexual Wellness Market to Witness 4.7% CAGR by 2031 | SkyQuest Technology - Benzinga
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com - Defense World
TherapeuticsMD announces revised shareholder proposal deadline By Investing.com - Investing.com Australia
TherapeuticsMD announces revised shareholder proposal deadline - Investing.com India
Tourmaline Bio (NASDAQ:TRML) Shares Up 3.9% - Defense World
This company generates no revenue and its market cap is over $20 billion. Here's why that valuation - The Bharat Express News
Commonwealth Equity Services LLC Has $979,000 Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX) - Defense World
WINTON GROUP Ltd Buys New Shares in Tactile Systems Technology, Inc. (NASDAQ:TCMD) - MarketBeat
TransMedics Stock: Take Profits While The Valuation Is Sky High (NASDAQ:TMDX) - Seeking Alpha
Somite’s SMT-M01 awarded US orphan drug designation for Duchenne muscular dystrophy - BioWorld Online
Transmedics Group Inc (TMDX) deserves deeper analysis - US Post News
This is why everyone is talking about Summit TherapeuticsTHE BHARAT EXPRESS NEWS - The Bharat Express News
Here's Why Everyone's Talking About Summit Therapeutics - The Motley Fool
An analyst sees good growth prospects for Transmedics Group Inc (TMDX) - SETE News
Implant maker Tenon Medical nearly triples its market capitalization in two days - Kursiv Media
TD Asset Management Inc Invests $2.08 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit lifts Instil, BioNTech on Merck beating data (NASDAQ:SMMT) - Seeking Alpha
Finanzdaten der Therapeuticsmd Inc-Aktie (TXMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Therapeuticsmd Inc-Aktie (TXMD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Collins Cooper C. | Director |
Aug 21 '24 |
Buy |
1.70 |
1,200 |
2,039 |
47,922 |
| Walker Marlan D | Chief Executive Officer |
Dec 05 '23 |
Option Exercise |
0.00 |
70,000 |
0 |
81,615 |
| Walker Marlan D | Chief Executive Officer |
Dec 06 '23 |
Sale |
2.31 |
14,500 |
33,496 |
67,115 |
| Walker Marlan D | Chief Executive Officer |
Dec 07 '23 |
Sale |
2.24 |
4,550 |
10,187 |
62,565 |
0.88%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):